I believe we have seen other Oracle Dispatch artic
Post# of 36568
(Total Views: 233)
Posted On: 01/18/2019 5:23:35 AM
I believe we have seen other Oracle Dispatch articles:
Why the Squeeze is on in Generex Biotechnology Corporation (OTCMKTS:GNBT)
By James Hudson - January 18, 2019
SHARE Facebook Twitter
If you haven’t been watching Generex Biotechnology Corporation (OTCMKTS:GNBT), you might want to start. The stock has been positively on fire in recent days in what looks for all the world to be genuine acceleration on strong accumulation. Shares are up over 100% on strengthening and strong volume in the past week, and there are several reasons why, one of which is likely the company’s recent announcement that it will dividend Generex shareholders with shares in its wholly-owned subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express), with the ultimate plan to spin out the company on a public exchange.
According to the release, “The dividend will be structured for Generex shareholders to receive 1 share of NuGenerex Immuno-Oncology for every 4 shares of Generex Biotechnology with the Record Date of Thursday, January 17, 2019, and a Payment Date of Monday, February 25, 2019.”
www.investingdaily.com
Generex Biotechnology Corporation (OTCMKTS:GNBT) bills itself as a company that, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States.
It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices.
The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.
According to company materials, “Generex Biotechnology Corp. (GNBT) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our company creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. The company goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.”
Why the Squeeze is on in Generex Biotechnology Corporation (OTCMKTS:GNBT)
By James Hudson - January 18, 2019
SHARE Facebook Twitter
If you haven’t been watching Generex Biotechnology Corporation (OTCMKTS:GNBT), you might want to start. The stock has been positively on fire in recent days in what looks for all the world to be genuine acceleration on strong accumulation. Shares are up over 100% on strengthening and strong volume in the past week, and there are several reasons why, one of which is likely the company’s recent announcement that it will dividend Generex shareholders with shares in its wholly-owned subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express), with the ultimate plan to spin out the company on a public exchange.
According to the release, “The dividend will be structured for Generex shareholders to receive 1 share of NuGenerex Immuno-Oncology for every 4 shares of Generex Biotechnology with the Record Date of Thursday, January 17, 2019, and a Payment Date of Monday, February 25, 2019.”
www.investingdaily.com
Generex Biotechnology Corporation (OTCMKTS:GNBT) bills itself as a company that, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States.
It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices.
The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.
According to company materials, “Generex Biotechnology Corp. (GNBT) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our company creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. The company goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.”
(0)
(0)